Lilly reports Phase 2b results for eloralintide plus tirzepatide in obesity with type 2 diabetes

30 September 2026 Combination P1 Primary public evidence Sponsor press release

On 30 September 2026 Lilly announced 48-week results from its Phase 2b EloraTZP trial in adults with obesity or overweight and type 2 diabetes (367 participants). The highest combination arm, eloralintide 9 mg plus tirzepatide 15 mg, had a mean weight change of -23.3% and an A1C change of -2.9%, against -14.8% and -2.4% for tirzepatide 15 mg alone. Stopping treatment because of adverse events ranged from 10.8% to 27.0% across the combination arms, against 2.9% for tirzepatide alone.

-23.3% vs -14.8%

Mean weight change at 48 weeks: eloralintide 9 mg plus tirzepatide 15 mg vs tirzepatide 15 mg alone

-2.9% vs -2.4%

Mean A1C change at 48 weeks, same two arms (average baseline A1C 8.1%)

10.8% to 27.0% vs 2.9%

Stopped treatment because of adverse events: all eloralintide plus tirzepatide arms vs tirzepatide alone

Background and context

What the registry says about the study

The announcement relates to NCT06603571, a Phase 2 study comparing eloralintide and tirzepatide, alone or together, with placebo in adults with obesity or overweight and type 2 diabetes. It runs under the chronic weight management master protocol (NCT06143956). The primary endpoint is percent change in body weight at week 48, and HbA1c is a registered secondary measure.

Who was eligible

Adults aged 18 to 75 with type 2 diabetes, an HbA1c from 7.0% to 10.5% and a BMI of at least 27. They were treated for at least three months with diet and exercise alone or with metformin, with or without an SGLT2 inhibitor.

What the registry does not show yet

The record is marked completed, with primary completion on 1 July 2026, but has no results posted. There is no registry results table to check the announced figures against. The weight change in the release is the registered primary measure, and the A1C change is a registered secondary measure.

Trial record: ClinicalTrials.gov NCT06603571, read on 2026-10-15. Registered plans can change.

Read with care

These are the sponsor's own announced results, presented at the EASD annual meeting in Milan. They are not a peer-reviewed publication, and the release states no p-values or confidence intervals, so this page does not describe any difference between arms as statistically significant.

The weight and A1C figures use the efficacy estimand, which Lilly defines as the efficacy had all randomized participants remained on study intervention (with possible dose interruptions or modifications) for 48 weeks. They describe what the analysis estimated under that assumption, not what every participant experienced.

Adverse-event discontinuation rates, as Lilly reports them: 10.8% to 27.0% across the eloralintide plus tirzepatide arms, 0% to 10.8% across the eloralintide-alone arms, 2.9% with tirzepatide alone and 16.7% with placebo. The placebo figure is higher than the tirzepatide figure, so these rates are not a clean ranking of tolerability. Lilly describes the most common adverse events as gastrointestinal, generally mild or moderate and occurring mainly while the treatment amount was being stepped up, and more frequent in the combination arms than with either medicine alone.

Eloralintide alone, in the same trial: mean weight change of -8.2% (3 mg), -12.3% (6 mg) and -11.1% (9 mg), against -3.0% with placebo. The lower combination arms reported -13.2% (3 mg plus tirzepatide 5 mg), -19.4% (6 mg plus 5 mg) and -19.9% (6 mg plus 10 mg).

The population is adults with type 2 diabetes. These figures are not directly comparable with eloralintide's separate Phase II obesity trial in people without diabetes. Eloralintide is investigational and not approved. Lilly says it plans to start Phase 3 trials of the combination in the fourth quarter of 2026; no Phase 3 result exists yet.

Source

Eli Lilly and Company, press release, 30 September 2026, presented at the 62nd EASD Annual Meeting, Milan

P1 Primary public evidence Sponsor press release. A sponsor announcement of preliminary results. It is not a peer-reviewed publication.

Figures checked against this source on 1 October 2026. How this site grades evidence

Related trial: NCT06603571 (ClinicalTrials.gov registration)